Company intelligence / Profile preview

HRA Pharma

Paris, Île-de-France, France

Ownership: Private
Development stage: Other

Overview

HRA Pharma is a leader in women’s health and endocrinology, having commercialized multiple OTC and Rx products, including the first levonorgestrel-based emergency contraceptive; it was acquired by Perrigo in May 2022 and operates as a key global division in self-care pharmaceuticals

Therapeutic areas: Women's HealthEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

R&D, manufacturing, and distribution collaborations across Europe, US, global NGOs; specifics not exhaustively listed

Beyond the preview

Go deeper on HRA Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRA Pharma.

Explore the full profile